Optimal Allocation of Resources across Four Interventions for Type 2 Diabetes

Background Several interventions can be applied to prevent complications of type 2 diabetes. This article examines the optimal allocation of resources across 4 interventions to treat patients newly diagnosed with type 2 diabetes. The interventions are intensive glycemic control, intensified hypertension control, cholesterol reduction, and smoking cessation. Methods A linear programming model was designed to select sets of interventions to maximize quality-adjusted life years (QALYs), subject to varied budget and equity constraints. Results For no additional cost, approximately 211,000 QALYs can be gained over the lifetimes of all persons newly diagnosed with diabetes by implementing interventions rather than standard care. With increased availability of funds, additional health benefits can be gained but with diminishing marginal returns. The impact of equity constraints is extensive compared to the solution with the same intervention costs and no equity constraint. Under the conditions modeled, intensified hypertension control and smoking cessation interventions were provided most often, and intensive glycemic control and cholesterol reduction interventions were provided less often. Conclusions A resource allocation model identifies trade-offs involved when imposing budget and equity constraints on care for individuals with newly diagnosed diabetes.

[1]  A. Bates,et al.  Prioritization of health care services. A progress report by the Oregon Health Services Commission. , 1991, Archives of internal medicine.

[2]  J. Baron,et al.  Cost-effectiveness analysis in a setting of budget constraints--is it equitable? , 1996, The New England journal of medicine.

[3]  Chen Mm,et al.  Maximizing health system output with political and administrative constraints using mathematical programming. , 1976 .

[4]  Roy M. Anderson,et al.  Spatial heterogeneity and the design of immunization programs , 1984 .

[5]  B. Davis,et al.  Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.

[6]  J. Rawles Castigating QALYs. , 1989, Journal of medical ethics.

[7]  E. H. Kaplan Economic Evaluation and HIV Prevention Community Planning , 1998 .

[8]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[9]  E. H. Kaplan Economic Evaluation and HIV Prevention Community Planning A Policy Analyst's Perspective , 1998 .

[10]  M L Brandeau,et al.  Optimal Investment in a Portfolio of HIV Prevention Programs , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.

[11]  Eric R. Zieyel Operations research : applications and algorithms , 1988 .

[12]  A. Zbrozek,et al.  Model of Complications of NIDDM: I. Model construction and assumptions , 1997, Diabetes Care.

[13]  K. Flegal,et al.  Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994 , 1998, Diabetes Care.

[14]  R. Kaplan Value Judgment in the Oregon Medicaid Experiment , 1994, Medical care.

[15]  D N Mendelson,et al.  Health care expenditures for people with diabetes mellitus, 1992. , 1994, The Journal of clinical endocrinology and metabolism.

[16]  康生 大久保,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study , 1995 .

[17]  E. Araki,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. , 1995, Diabetes research and clinical practice.

[18]  Robert Fabian,et al.  Valuing health for policy : an economic approach , 1995 .

[19]  J. Kahn,et al.  The cost-effectiveness of HIV prevention targeting: how much more bang for the buck? , 1996, American journal of public health.

[20]  A. Zbrozek,et al.  Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia , 1997, Diabetes Care.

[21]  Ronald L. Rardin,et al.  Optimization in operations research , 1997 .

[22]  A Gafni,et al.  Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. , 1993, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[23]  R. Carr-Hill,et al.  Assumptions of the QALY procedure. , 1989, Social science & medicine.

[24]  T O Tengs,et al.  Oregon's Medicaid Ranking and Cost- Effectiveness , 1996, Medical decision making : an international journal of the Society for Medical Decision Making.

[25]  Edward H. Kaplan,et al.  Allocating HIV prevention resources , 1998 .

[26]  D. Hadorn The Oregon Priority-setting Exercise , 1996, Medical decision making : an international journal of the Society for Medical Decision Making.

[27]  P. Macfarlane,et al.  West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .

[28]  R. Nelson,et al.  Justice and the moral acceptability of rationing medical care: the Oregon experiment. , 1992, The Journal of medicine and philosophy.

[29]  G S Zaric,et al.  Resource allocation for epidemic control over short time horizons. , 2001, Mathematical biosciences.

[30]  A A Stinnett,et al.  Mathematical programming for the efficient allocation of health care resources. , 1996, Journal of health economics.

[31]  A. Hillman,et al.  Competing Practice Guidelines: Using Cost-Effectiveness Analysis To Make Optimal Decisions , 1998, Annals of Internal Medicine.

[32]  S M Teutsch,et al.  The role of resource allocation models in selecting clinical preventive services. , 1999, The American journal of managed care.

[33]  Anke Richter,et al.  Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. , 2002, JAMA.

[34]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[35]  S. Cobbe Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. , 1997, The American journal of cardiology.

[36]  A H van Zon,et al.  Patient flows and optimal health‐care resource allocation at the macro‐level: a dynamic linear programming approach , 1999, Health care management science.

[37]  J. Blumstein The Oregon experiment: the role of cost-benefit analysis in the allocation of Medicaid funds. , 1997, Social science & medicine.

[38]  E. Nord Health Status Index Models for Use in Resource Allocation Decisions: A Critical Review in the Light of Observed Preferences for Social Choice , 1996, International Journal of Technology Assessment in Health Care.

[39]  D K Owens,et al.  An Analysis of Optimal Resource Allocation for Prevention of Infection with Human Immunodeficiency Virus (HIV) in Injection Drug Users and Non-Users , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.

[40]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[41]  P. Singer Resource allocation: beyond evidence-based medicine and cost-effectiveness analysis. , 1997, ACP journal club.

[42]  V. Hasselblad,et al.  Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. , 1997, JAMA.

[43]  Herbert W. Hethcote,et al.  Epidemiological models for heterogeneous populations: proportionate mixing, parameter estimation, and immunization programs , 1987 .

[44]  N. Ray,et al.  Economic Consequences of Diabetes Mellitus in the U.S. in 1997 , 1998, Diabetes Care.

[45]  Milton C. Weinstein,et al.  Valuing health care: From cost–effectiveness ratios to resource allocation: where to draw the line? , 1995 .